Kinnate Biopharma Inc. Appoints Neha Krishnamohan as CFO and Executive Vice President, Corporate Development and Expands its Leadership Team with Key New Hires
June 07, 2021 08:00 ET | Kinnate Biopharma
Experienced leaders bring substantial clinical research, regulatory, and operational expertise in the biopharmaceutical industry to the Kinnate team SAN FRANCISCO and SAN DIEGO, June 07, 2021 ...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. Presents Preclinical Data From its Lead RAF Inhibitor Candidate KIN-2787 at ASCO 2021
June 04, 2021 08:00 ET | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. to Participate at the Goldman Sachs 42nd Annual Global Healthcare Conference
May 25, 2021 16:05 ET | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. Reports First Quarter 2021 Financial Results and Announces FDA Clearance of Investigational New Drug Application for KIN-2787
May 17, 2021 16:05 ET | Kinnate Biopharma
KIN-2787 is the company’s RAF inhibitor candidate for patients with mutant BRAF-driven solid tumors Planned initiation of Phase 1 clinical trial for KIN-2787 in mid-2021 Ended the quarter with cash...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture
May 13, 2021 16:02 ET | Kinnate Biopharma
Financing led by OrbiMed Asia Partners, with participation from OrbiMed Private Investments and Foresite CapitalThe joint venture will have exclusive license to develop and commercialize Kinnate’s...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. Announces the Departure of Dr. Stephen Kaldor from its Board of Directors
April 30, 2021 08:00 ET | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, April 30, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. Reports Full Year 2020 Financial Results
March 29, 2021 16:05 ET | Kinnate Biopharma
Completed recent IPO, raising $276MM in gross proceeds to fund kinase inhibitors for genomically defined cancers Progress towards IND filing for KIN-2787, our RAF inhibitor candidate, in the...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. Announces Its Addition to the Russell 2000® Index
March 19, 2021 16:05 ET | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, March 19, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
February 11, 2021 16:05 ET | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate_LogoColor@10x
Kinnate Biopharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
December 07, 2020 16:05 ET | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...